Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Recommendation of “Buy” by Brokerages
Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) have been assigned an average recommendation of “Buy” from the seven analysts that are presently covering the company, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have covered the stock in […]
Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) have been assigned an average recommendation of “Buy” from the seven analysts that are presently covering the company, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have covered the stock in […]
